Idelalisib Patent Expiration

Idelalisib is used for disrupting leukocyte function, specifically for the treatment of CLL, FL, or SLL, and in combination with rituximab. It was first introduced by Gilead Sciences Inc in its drug Zydelig on Jul 23, 2014.


Idelalisib Patents

Given below is the list of patents protecting Idelalisib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zydelig US10730879 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one Mar 05, 2033 Gilead Sciences Inc
Zydelig US6800620 Inhibitors of human phosphatidylinositol 3-kinase delta Apr 24, 2021

(Expired)

Gilead Sciences Inc
Zydelig US6949535 Inhibitors of human phosphatidyl-inositol 3-kinase delta Apr 24, 2021

(Expired)

Gilead Sciences Inc
Zydelig US8138195 Inhibitors of human phosphatidylinositol 3-kinase delta Apr 24, 2021

(Expired)

Gilead Sciences Inc
Zydelig US8492389 Inhibitors of human phosphatidylinositol 3-kinase delta Apr 24, 2021

(Expired)

Gilead Sciences Inc
Zydelig US8637533 Inhibitors of human phosphatidylinositol 3-kinase delta Apr 24, 2021

(Expired)

Gilead Sciences Inc
Zydelig US8865730 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one Mar 05, 2033 Gilead Sciences Inc
Zydelig US8980901 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta May 12, 2025 Gilead Sciences Inc
Zydelig US9149477 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta May 12, 2025 Gilead Sciences Inc
Zydelig US9469643 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one Sep 02, 2033 Gilead Sciences Inc
Zydelig US9492449 Therapies for hematologic malignancies Mar 11, 2030 Gilead Sciences Inc
Zydelig USRE44599 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta Jul 21, 2025 Gilead Sciences Inc
Zydelig USRE44638 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta Aug 05, 2025 Gilead Sciences Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Idelalisib's patents.

Given below is the list recent legal activities going on the following patents of Idelalisib.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 01 May, 2024 US9492449
Expire Patent 22 Apr, 2024 US8138195
Payment of Maintenance Fee, 8th Year, Large Entity 03 Apr, 2024 US9469643
Payment of Maintenance Fee, 4th Year, Large Entity 17 Jan, 2024 US10730879
Maintenance Fee Reminder Mailed 06 Nov, 2023 US8138195
Payment of Maintenance Fee, 8th Year, Large Entity 22 Mar, 2023 US9149477
Payment of Maintenance Fee, 8th Year, Large Entity 31 Aug, 2022 US8980901
Correspondence Address Change 26 Apr, 2022 US10730879
Payment of Maintenance Fee, 8th Year, Large Entity 06 Apr, 2022 US8865730
Expire Patent 07 Mar, 2022 US8637533



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳